微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 36.62% | -6.36% | -7.24% | 96/157 | 50.55% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 39.48% | -1.64% | 1.8% | 91/157 | 50.61% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 38.78% | -3.28% | -0.22% | 95/157 | -2.2% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 38.86% | -9.39% | -0.61% | 93/157 | 14.83% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 39.1% | -1.6% | -2.57% | 95/157 | 31.96% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 40.13% | -10.04% | 0.1% | 101/157 | 51.88% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 40.09% | -11.85% | -6.53% | 98/157 | 22.51% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 42.89% | -10.6% | 7.93% | 92/157 | 33.12% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 39.74% | -13.08% | -10.93% | 93/157 | 51.76% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 44.61% | -22.07% | -1.91% | 94/157 | 51.61% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 45.48% | -23.72% | -5.2% | 91/157 | 32.47% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 47.98% | -19.73% | 4.93% | 85/157 | 38.42% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 45.72% | -24.96% | -20.13% | 88/157 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 57.25% | -11.47% | -3.99% | 67/157 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 59.63% | -7.3% | -0.24% | 55/157 | 5.64% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 59.77% | -13.15% | -1.91% | 58/157 | 20.99% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 60.93% | -7.09% | -5.77% | 54/157 | 54.39% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 64.66% | -14.23% | 0.53% | 53/157 | 55.2% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 64.32% | -21.18% | -6.54% | 47/157 | 46.77% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 68.82% | -16.48% | 4.95% | 39/157 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 65.58% | -21.97% | -13.02% | 36/157 | 54.13% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 75.39% | 3.11% | -7.62% | 29/157 | -148.64% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 81.61% | 13.57% | -0.96% | 19/157 | 56.43% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 82.4% | 20.19% | -1.95% | 13/157 | 54.17% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 84.04% | 30.98% | 14.93% | 12/157 | 55.17% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 73.12% | 4.67% | 1.75% | 31/157 | -1242.15% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 71.86% | 1.89% | 4.82% | 25/157 | 55.23% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 68.56% | -0.24% | 6.85% | 31/157 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 64.16% | 2% | -8.15% | 32/157 | 51.07% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 69.85% | 31.56% | -0.96% | 35/157 | -211.97% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 70.53% | 2% | 2.62% | 22/157 | 54.14% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 68.72% | 2% | 29.44% | 24/157 | 53.53% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 53.1% | 64.55% | 64.55% | 57/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2016-12-31 | 32.27% | 39.51% | 39.51% | 84/157 | 48.46% | 贝达药业 | 95.74% | 行业排名> |